Sacubitrilat
Prediabetes Syndrome
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Ohio State University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03938389CT.gov The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prediabetes Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sacubitrilat (this asset) | Ohio State University | Approved | BB · 65 |
| Metformin | Yu Chen | P4 | A |
| Liraglutide | Woman's | P4 | BBB |
| Semaglutide | Esbjerg Hospital - University Hospital of Southern Denmark | P4 | BBB |
| Exenatide | RenJi Hospital | P4 | BBB |
| Empagliflozin | The University of Texas Health Science Center at San Antonio | P4 | BBB |
| Sitagliptin | Vanderbilt University Medical Center | P4 | BB |
| Pioglitazone | VA Office of Research and Development | P4 | BB |
| Dapagliflozin | Centro Medico Nacional Siglo XXI IMSS | P2/3 | BB |
+42 more in the Prediabetes Syndrome cohort
Other indications for Sacubitrilat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Essential Hypertension | — | P4 | BB · 65 |
| Hypertensive Disorder | — | P3 | BB · 64 |
| Neoplasm | — | P1/2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Sacubitrilat in Prediabetes Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/sacubitrilat-prediabetes-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →